The Innovation Center for Translational Imaging of Tel Aviv University acquires MILabs VECTor PET/SPECT/CT system

Cleansweep Live Auction Thursday Jan. 21th 10AM EST - Pre-Bid Now
California Auction Event Closing Jan. 26th - Bid Now

The Innovation Center for Translational Imaging of Tel Aviv University acquires MILabs VECTor PET/SPECT/CT system

Press releases may be edited for formatting or style | July 09, 2019 Molecular Imaging
Tel Aviv and Utrecht, July 9 2019 - Tel Aviv University’s (TAU) new Translational Medical Research Center has acquired a VECTor PET/SPECT/CT to help bridge the gap between academic discoveries and new products that benefit patients. The system will be installed at Sackler Cellular and Molecular Imaging Center (SCMIC), which will serve as the core imaging facility.

The head of the center is Tel Aviv University Cancer Biology Research Center chairperson Prof. Dan Peer. Prof. Peer explains that the center's goal is to strengthen the Israeli drug industry by accelerating bench discoveries into the clinic. “Due to the high resolution of its multiple modalities, MILabs VECTor is expected to be great tool since its visual acuity for imaging animals is similar to the one achievable in the clinic with human patients”

Prof. Ilan Tsarfaty, Director of Sackler Cellular and Molecular Imaging Center (SCMIC) adds:’ We are excited about the addition of this innovative multimodal in vivo translational imaging system to our core imaging facility.”

Servicing GE/Siemens Nuclear Medicine equipment with OEM trained engineers

Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.

According to Prof. Beekman, CEO/CSO MILabs B.V. “While the visual acuity of our PET/SPECT and CT modalities are indeed outstanding, we believe that the one-to-one translation of PET and SPECT results by simultaneous imaging of co-injected tracers will significantly contribute to a quick translation of in vivo research results to clinical trials”

About TAU Translational Medicine Center:
The center is modeled after a revolutionary approach to drug research first adopted by universities such as Harvard, Stanford and New York University. It replaces the traditional drug development model whereby only pharma/VC companies pay for the proof-of-concept and early clinical trials of drug candidates. For more info:

About MILabs B.V.
This Dutch company has a history of providing innovations to expand the applications of in-vivo imaging using PET, SPECT, Optical and X-ray CT. Available in any combination or as stand-alone systems, MILabs preclinical imaging modalities are globally recognized for being able to deliver the highest quality small-animal molecular, functional and anatomical images.

For more information, visit: or contact MILabs at

You Must Be Logged In To Post A Comment